ClinicalTrials.gg
CompletedNCT00555620Updated Jan 14, 2013Results posted

Study Of Sunitinib In Combination With Cisplatin/Capecitabine Or Oxaliplatin/Capecitabine In Patients With Advanced Gastric Cancer

A Phase 1 interventional study of capecitabine and oxaliplatin in Stomach Neoplasms, sponsored by Pfizer. Completed at 3 sites in Korea, Republic of. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-01-14.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
76
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 131 studies testing oxaliplatin in Stomach Neoplasms — 18 open to participants now, 23 under way, 6 of them phase 3. Oxaliplatin · Stomach Neoplasms.

Enrollment
47th of 129
76 · median 51
Started
2008
with 5 others
Phase 1
15 of 131
2 open now
Registered
30th of 131
by date

Among the 131 studies testing oxaliplatin in Stomach Neoplasms, this one is the 47th largest by enrollment of the 129 interventional ones that give a count, is one of 6 that started in 2008, is one of 15 in phase 1, and was the 30th registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

18 of the 131 studies testing oxaliplatin in Stomach Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About oxaliplatin

Oxaliplatin: first FDA approval 2002 (ELOXATIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies testing oxaliplatin in Stomach Neoplasms, or all of them as a file.
02

Study summary

The purpose of the study is to determine the safe and tolerable doses of sunitinib given together with either cisplatin and capecitabine or oxaliplatin and capecitabine in patients who have advanced gastric cancer who have not received prior chemotherapy for their advanced cancer

03

Conditions studied

  • Stomach Neoplasms

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed diagnosis of stomach cancer
  • advanced stomach cancer of stage IV
  • adequate blood chemistry, blood counts and kidney function
  • willing to participate to study requirements and sign an document

Exclusion criteria

Exclusion Criteria:

  • prior chemotherapy for the stomach cancer in its advanced stage
  • excessive toxicities related to prior therapies
  • pregnant or breastfeeding patients
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
76 participants (actual)

Study arms

  • Experimental
    A

    Drug: capecitabine · Drug: oxaliplatin · Drug: sunitinib malate

  • Experimental
    B

    Drug: capecitabine · Drug: cisplatin · Drug: sunitinib malate

Interventions

  • Capecitabine is given orally at 1000mg/m\^2 twice a day for 14 days followed by 7 days of drug free period.

  • Oxaliplatin is given 110mg/m\^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.

  • sunitinib is given orally 25mg/day for 14 days followed by 7 days of drug free period.

    Also known as: Sutent

  • Capecitabine is given orally at 1000mg/m\^2 twice a day for 14 days followed by 7 days of drug free period.

  • Cisplatin is given 80mg/m\^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.

  • sunitinib is given orally 25mg/day for 14 days followed by 7 days of drug free period.

06

What researchers measure

Primary outcomes

  1. Number of Participants With First-cycle Dose Limiting Toxicities (DLTs)

    Any DLT event in Cycle 1: Grade (GR) 3/4 nausea, vomiting, or diarrhea despite anti-emetics, anti-diarrheals; GR 3 nonhematological toxicity for greater than or equal to (≥)7 days (except alopecia, skin or hair discoloration, hyperamylasemia, or hyperlipasemia without other clinical evidence of pancreatitis and asymptomatic hyperuricemia); GR 4 nonhematological toxicity; GR 4 neutropenia ≥7 days or thrombocytopenia; GR ≥3 febrile neutropenia or neutropenic infection; GR 3 thrombocytopenia ≥7 days; any treatment-related toxicity having \>3 consecutive CAP or SU missed doses per cycle; delayed toxicity recovery \>14 days.

    Time frame: Baseline up to Day 21

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of SU, SU012662 (Metabolite of SU), and Total Drug (SU + SU012662)

    Time frame: Day 14 of Cycle 1 (predose and 2, 4, 6, 8, 10, and 24 hours postdose)

  2. Cmax of CAP

    Time frame: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)

  3. Cmax of 5'-Deoxy-5-fluorocytidine (Metabolite of CAP, 5'DFCR)

    Time frame: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)

  4. Cmax of 5'-Deoxy-5-fluorouridine (Metabolite of CAP, 5'DFUR)

    Time frame: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)

  5. Cmax of 5-fluorouracil (Metabolite of CAP, 5-FU)

    Time frame: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)

  6. Minimum Observed Plasma Trough Concentration (Cmin) of SU, SU012662, and Total Drug (SU + SU012662)

    Time frame: Day 14 of Cycle 1 (predose and 2, 4, 6, 8, 10, and 24 hours postdose)

  7. Cmin of CAP

    Time frame: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)

  8. Cmin of 5'DFCR

    Time frame: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)

  9. Cmin of 5'DFUR

    Time frame: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)

  10. Cmin of 5-FU

    Time frame: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)

  11. Time to Reach Maximum Observed Plasma Concentration (Tmax) for SU, SU012662, and Total Drug (SU + SU012662)

    Time frame: Day 14 of Cycle 1 (predose and 2, 4, 6, 8, 10, and 24 hours postdose)

  12. Tmax for CAP

    Time frame: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)

  13. Tmax for 5'DFCR

    Time frame: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)

  14. Tmax for 5'DFUR

    Time frame: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)

  15. Tmax for 5-FU

    Time frame: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)

  16. Terminal Elimination Half-Life (t1/2) for SU, SU012662, and Total Drug (SU + SU012662)

    Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

    Time frame: Day 14 of Cycle 1 (predose and 2, 4, 6, 8, 10, and 24 hours postdose)

  17. t1/2 for CAP

    Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

    Time frame: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)

  18. t1/2 for 5'DFCR

    Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

    Time frame: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)

  19. t1/2 for 5'DFUR

    Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

    Time frame: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)

  20. t1/2 for 5-FU

    Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

    Time frame: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)

  21. Area Under the Curve From Time 0 to 24 Hours Postdose (AUC [0-24]) for SU, SU012662, and Total Drug (SU + SU012662)

    Area under the plasma concentration-time curve from time 0 to 24 hours postdose (0-24), also considered the AUC between doses at steady state.

    Time frame: Day 14 of Cycle 1 (predose and 2, 4, 6, 8, 10, and 24 hours postdose)

  22. Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]: CAP, 5'DFCR, 5'DFUR, and 5-FU

    AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (predose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).

    Time frame: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)

  23. Area Under the Curve From Time Zero to 12 Hours [AUC (12)] for CAP, 5'DFCR, 5'DFUR, and 5-FU

    AUC (12) = Area under the plasma concentration versus time curve from time zero (predose) to the extrapolated time 12 hours postdose. It is obtained from AUC (0 - last) plus AUC (last - 12)

    Time frame: Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)

  24. Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for CAP

    Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)

    Time frame: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose) and Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours)

  25. AUClast for 5'DFCR

    Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)

    Time frame: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose) and Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours)

  26. AUClast for 5'DFUR

    Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)

    Time frame: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose) and Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours)

  27. AUClast for 5-FU

    Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)

    Time frame: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose) and Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours)

  28. Percentage of Participants With Objective Response

    Percentage of participants with an objective response-based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). CR defined as the disappearance of all target lesions. PR defined as ≥30 percent (%) decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.

    Time frame: Baseline, Day 21 of every even-numbered cycle up to 15 months

  29. Duration of Response (DR)

    DR defined as time from start of first documented objective tumor response (CR or PR) to first documented objective tumor progression or death due to any cause, whichever occurs first.

    Time frame: Baseline up to Month 15

  30. Progression-Free Survival (PFS)

    PFS defined as time from the first dose of study treatment to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first.

    Time frame: Baseline up to Month 15

07

Results

Posted Sep 5, 2011

Participant flow

Participant flow — Overall Study
MilestoneSU 37.5 mg, CIS 60 mg/m^2, CAP 1600 mg/m^2SU 37.5 mg, CIS 60 mg/m^2, CAP 2000 mg/m^2SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2SU 37.5 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2
Started671523322
Completed000000
Not completed671523322
Withdrew: Death010001
Withdrew: Study terminated by sponsor001000
Withdrew: Adverse event001501
Withdrew: Objective progression or relapse651217316
Withdrew: Participant refused treatment011001
Withdrew: Other000103

Outcome measures

PrimaryNumber of Participants With First-cycle Dose Limiting Toxicities (DLTs)

Any DLT event in Cycle 1: Grade (GR) 3/4 nausea, vomiting, or diarrhea despite anti-emetics, anti-diarrheals; GR 3 nonhematological toxicity for greater than or equal to (≥)7 days (except alopecia, skin or hair discoloration, hyperamylasemia, or hyperlipasemia without other clinical evidence of pancreatitis and asymptomatic hyperuricemia); GR 4 nonhematological toxicity; GR 4 neutropenia ≥7 days or thrombocytopenia; GR ≥3 febrile neutropenia or neutropenic infection; GR 3 thrombocytopenia ≥7 days; any treatment-related toxicity having \>3 consecutive CAP or SU missed doses per cycle; delayed toxicity recovery \>14 days.

Time frame:
Baseline up to Day 21
Reported as:
Number · participants
Number of Participants With First-cycle Dose Limiting Toxicities (DLTs)
participantsSU 37.5 mg, CIS 60 mg/m^2, CAP 1600 mg/m^2SU 37.5 mg, CIS 60 mg/m^2, CAP 2000 mg/m^2SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2SU 37.5 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2
Number of Participants With First-cycle Dose Limiting Toxicities (DLTs)103220
SecondaryMaximum Observed Plasma Concentration (Cmax) of SU, SU012662 (Metabolite of SU), and Total Drug (SU + SU012662)
Time frame:
Day 14 of Cycle 1 (predose and 2, 4, 6, 8, 10, and 24 hours postdose)
Reported as:
Mean · nanograms per milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax) of SU, SU012662 (Metabolite of SU), and Total Drug (SU + SU012662)
nanograms per milliliter (ng/mL)SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2
Cmax SU01124840.1 ± 10.869.7 ± 17.646.5 ± 10.8
Cmax SU01266214.0 ± 11.323.7 ± 9.916.6 ± 3.3
Cmax total drug (SU011248+SU012662)53.9 ± 22.193.0 ± 24.962.4 ± 13.4
SecondaryCmax of CAP
Time frame:
Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
Reported as:
Mean · ng/mL
Cmax of CAP
ng/mLSU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2
Cycle 1, Day 17000 ± 73542051 ± 110911681 ± 8034
Cycle 1, Day 1420491 ± 270981989 ± 168616276 ± 15832
SecondaryCmax of 5'-Deoxy-5-fluorocytidine (Metabolite of CAP, 5'DFCR)
Time frame:
Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
Reported as:
Mean · ng/mL
Cmax of 5'-Deoxy-5-fluorocytidine (Metabolite of CAP, 5'DFCR)
ng/mLSU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2
Cycle 1, Day 14800 ± 8633352 ± 12558017 ± 3692
Cycle 1, Day 145500 ± 59822267 ± 9338036 ± 3540
SecondaryCmax of 5'-Deoxy-5-fluorouridine (Metabolite of CAP, 5'DFUR)
Time frame:
Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
Reported as:
Mean · ng/mL
Cmax of 5'-Deoxy-5-fluorouridine (Metabolite of CAP, 5'DFUR)
ng/mLSU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2
Cycle 1, Day 14010 ± 19092891 ± 10997166 ± 4073
Cycle 1, Day 146259 ± 73812074 ± 76510082 ± 5421
SecondaryCmax of 5-fluorouracil (Metabolite of CAP, 5-FU)
Time frame:
Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
Reported as:
Mean · ng/mL
Cmax of 5-fluorouracil (Metabolite of CAP, 5-FU)
ng/mLSU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2
Cycle 1, Day 1176 ± 127165 ± 63495 ± 326
Cycle 1, Day 14552 ± 641153 ± 78866 ± 473
SecondaryMinimum Observed Plasma Trough Concentration (Cmin) of SU, SU012662, and Total Drug (SU + SU012662)
Time frame:
Day 14 of Cycle 1 (predose and 2, 4, 6, 8, 10, and 24 hours postdose)
Reported as:
Mean · ng/mL
Minimum Observed Plasma Trough Concentration (Cmin) of SU, SU012662, and Total Drug (SU + SU012662)
ng/mLSU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2
Cmin SU01124829.0 ± 5.249.2 ± 13.030.2 ± 9.2
Cmin SU01266211.9 ± 9.318.7 ± 7.911.1 ± 2.6
Cmin total drug (SU011248+SU012662)41.6 ± 15.668.5 ± 16.441.8 ± 11.3
SecondaryCmin of CAP
Time frame:
Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
Reported as:
Mean · ng/mL
Cmin of CAP
ng/mLSU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2
Cycle 1, Day 124.8 ± 35.10.0 ± 0.00.0 ± 0.0
Cycle 1, Day 1432.0 ± 45.20.0 ± 0.00.0 ± 0.0
SecondaryCmin of 5'DFCR
Time frame:
Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
Reported as:
Mean · ng/mL
Cmin of 5'DFCR
ng/mLSU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2
Cycle 1, Day 111.1 ± 15.713.0 ± 20.755.60 ± 100.9
Cycle 1, Day 1450.5 ± 71.40.00 ± 0.000.00 ± 0.00
SecondaryCmin of 5'DFUR
Time frame:
Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
Reported as:
Mean · ng/mL
Cmin of 5'DFUR
ng/mLSU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2
Cycle 1, Day 10.0 ± 0.02.4 ± 7.134.4 ± 69.0
Cycle 1, Day 1433.5 ± 47.40.0 ± 0.00.0 ± 0.0
SecondaryCmin of 5-FU
Time frame:
Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
Reported as:
Mean · ng/mL
Cmin of 5-FU
ng/mLSU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2
Cycle 1, Day 10.0 ± 0.00.0 ± 0.00.8 ± 2.5
Cycle 1, Day 140.0 ± 0.00.0 ± 0.00.0 ± 0.0
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax) for SU, SU012662, and Total Drug (SU + SU012662)
Time frame:
Day 14 of Cycle 1 (predose and 2, 4, 6, 8, 10, and 24 hours postdose)
Reported as:
Median · hour (hr)
Time to Reach Maximum Observed Plasma Concentration (Tmax) for SU, SU012662, and Total Drug (SU + SU012662)
hour (hr)SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2
Tmax SU0112484.0 (4.0 to 4.0)8.0 (2.0 to 10.0)8.0 (4.0 to 10.0)
Tmax SU0126629.0 (8.0 to 10.0)8.0 (4.0 to 24.0)6.0 (0.0 to 10.0)
Tmax total drug (SU011248+SU012662)4.0 (4.0 to 4.0)8.0 (2.0 to 10.0)6.0 (4.0 to 10.0)
SecondaryTmax for CAP
Time frame:
Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
Reported as:
Median · hr
Tmax for CAP
hrSU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2
Cycle 1, Day 14.3 (0.5 to 8.0)2.0 (0.5 to 3.0)0.5 (0.3 to 4.0)
Cycle 1, Day 140.3 (0.3 to 0.3)2.0 (0.5 to 4.0)0.4 (0.0 to 3.0)
SecondaryTmax for 5'DFCR
Time frame:
Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
Reported as:
Median · hr
Tmax for 5'DFCR
hrSU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2
Cycle 1, Day 14.3 (0.5 to 8.0)2.0 (0.5 to 4.0)0.6 (0.5 to 4.0)
Cycle 1, Day 140.4 (0.3 to 0.5)3.0 (0.9 to 4.0)0.5 (0.0 to 3.0)
SecondaryTmax for 5'DFUR
Time frame:
Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
Reported as:
Median · hr
Tmax for 5'DFUR
hrSU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2
Cycle 1, Day 14.5 (1.0 to 8.0)2.0 (0.5 to 4.0)0.8 (0.5 to 4.0)
Cycle 1, Day 140.4 (0.3 to 0.5)3.0 (0.9 to 4.0)0.5 (0.0 to 3.0)
SecondaryTmax for 5-FU
Time frame:
Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
Reported as:
Median · hr
Tmax for 5-FU
hrSU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2
Cycle 1, Day 14.5 (1.0 to 8.0)2.0 (0.5 to 4.0)0.6 (0.3 to 4.0)
Cycle 1, Day 140.4 (0.3 to 0.5)3.0 (0.5 to 4.0)0.5 (0.0 to 3.0)
SecondaryTerminal Elimination Half-Life (t1/2) for SU, SU012662, and Total Drug (SU + SU012662)

Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

Time frame:
Day 14 of Cycle 1 (predose and 2, 4, 6, 8, 10, and 24 hours postdose)

No measurements were reported for this outcome.

Secondaryt1/2 for CAP

Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

Time frame:
Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
Reported as:
Mean · hr
t1/2 for CAP
hrSU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2
Cycle 1, Day 10.3 ± NA0.3 ± NA0.4 ± 0.11
Cycle 1, Day 140.4 ± NA0.5 ± NA0.4 ± 0.12
Secondaryt1/2 for 5'DFCR

Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

Time frame:
Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
Reported as:
Mean · hr
t1/2 for 5'DFCR
hrSU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2
Cycle 1, Day 10.7 ± NA1.0 ± 0.40.8 ± 0.2
Cycle 1, Day 140.7 ± NA1.1 ± 0.70.8 ± 0.1
Secondaryt1/2 for 5'DFUR

Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

Time frame:
Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
Reported as:
Mean · hr
t1/2 for 5'DFUR
hrSU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2
Cycle 1, Day 10.7 ± NA1.0 ± 0.40.7 ± 0.1
Cycle 1, Day 140.6 ± NA1.0 ± 0.50.7 ± 0.1
Secondaryt1/2 for 5-FU

Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

Time frame:
Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
Reported as:
Mean · hr
t1/2 for 5-FU
hrSU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2
Cycle 1, Day 10.8 ± NA1.2 ± 0.80.6 ± 0.1
Cycle 1, Day 140.6 ± NA1.1 ± 0.40.6 ± 0.1
SecondaryArea Under the Curve From Time 0 to 24 Hours Postdose (AUC [0-24]) for SU, SU012662, and Total Drug (SU + SU012662)

Area under the plasma concentration-time curve from time 0 to 24 hours postdose (0-24), also considered the AUC between doses at steady state.

Time frame:
Day 14 of Cycle 1 (predose and 2, 4, 6, 8, 10, and 24 hours postdose)
Reported as:
Mean · nanogram hours per milliliter (ng*hr/mL)
Area Under the Curve From Time 0 to 24 Hours Postdose (AUC [0-24]) for SU, SU012662, and Total Drug (SU + SU012662)
nanogram hours per milliliter (ng*hr/mL)SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2
AUC (0-24) SU011248844 ± 1551420 ± 379902 ± 230
AUC (0-24) SU012662321 ± 254524 ± 219327 ± 64
AUC (0-24) total drug (SU011248+SU012662)1163 ± 4071944 ± 5331230 ± 273
SecondaryArea Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]: CAP, 5'DFCR, 5'DFUR, and 5-FU

AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (predose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).

Time frame:
Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
Reported as:
Mean · ng*hr/mL
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]: CAP, 5'DFCR, 5'DFUR, and 5-FU
ng*hr/mLSU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2
CAP (n = 1, 4, 10)7480 ± NA2828 ± 2158069 ± 3877
5'DFCR (n = 1, 7, 10)9200 ± NA8853 ± 164811467 ± 2476
5'DFUR (n = 1, 6, 10)7770 ± NA5703 ± 12959099 ± 2288
5-FU (n = 1, 5, 9)386 ± NA285 ± 119489 ± 190
SecondaryArea Under the Curve From Time Zero to 12 Hours [AUC (12)] for CAP, 5'DFCR, 5'DFUR, and 5-FU

AUC (12) = Area under the plasma concentration versus time curve from time zero (predose) to the extrapolated time 12 hours postdose. It is obtained from AUC (0 - last) plus AUC (last - 12)

Time frame:
Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
Reported as:
Mean · ng*hr/mL
Area Under the Curve From Time Zero to 12 Hours [AUC (12)] for CAP, 5'DFCR, 5'DFUR, and 5-FU
ng*hr/mLSU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2
CAP (n = 1, 4, 9)25435 ± NA2663 ± 4528865 ± 6533
5'DFCR (n = 1, 7, 10)15522 ± NA7087 ± 122210091 ± 2847
5'DFUR (n = 1, 6, 10)15522 ± NA4822 ± 122210291 ± 3675
5-FU (n = 1, 5, 10)1299 ± NA353 ± 141842 ± 403
SecondaryArea Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for CAP

Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)

Time frame:
Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose) and Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours)
Reported as:
Mean · ng*hr/mL
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for CAP
ng*hr/mLSU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2
Cycle 1, Day 17555 ± 1352899 ± 15807373 ± 4199
Cycle 1, Day 1413532 ± 166483157 ± 11718213 ± 6432
SecondaryAUClast for 5'DFCR

Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)

Time frame:
Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose) and Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours)
Reported as:
Mean · ng*hr/mL
AUClast for 5'DFCR
ng*hr/mLSU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2
Cycle 1, Day 112815 ± 54948028 ± 196311229 ± 2516
Cycle 1, Day 148614 ± 84776464 ± 13779776 ± 2868
SecondaryAUClast for 5'DFUR

Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)

Time frame:
Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose) and Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours)
Reported as:
Mean · ng*hr/mL
AUClast for 5'DFUR
ng*hr/mLSU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2
Cycle 1, Day 18855 ± 17615658 ± 12378951 ± 2248
Cycle 1, Day 148500 ± 91924829 ± 101510017 ± 3637
SecondaryAUClast for 5-FU

Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)

Time frame:
Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose) and Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours)
Reported as:
Mean · ng*hr/mL
AUClast for 5-FU
ng*hr/mLSU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2
Cycle 1, Day 1355 ± 27291 ± 95506 ± 200
Cycle 1, Day 14688 ± 802350 ± 129854 ± 390
SecondaryPercentage of Participants With Objective Response

Percentage of participants with an objective response-based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). CR defined as the disappearance of all target lesions. PR defined as ≥30 percent (%) decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.

Time frame:
Baseline, Day 21 of every even-numbered cycle up to 15 months
Reported as:
Number · percentage of participants
Percentage of Participants With Objective Response
percentage of participantsSU 37.5 mg, CIS 60 mg/m^2, CAP 1600 mg/m^2SU 37.5 mg, CIS 60 mg/m^2, CAP 2000 mg/m^2SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2SU 37.5 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2
Percentage of Participants With Objective Response16.7 (0.4 to 64.1)42.9 (9.9 to 81.6)46.7 (21.3 to 73.4)43.5 (23.2 to 65.5)0 (0.0 to 70.8)45.5 (24.4 to 67.8)
SecondaryDuration of Response (DR)

DR defined as time from start of first documented objective tumor response (CR or PR) to first documented objective tumor progression or death due to any cause, whichever occurs first.

Time frame:
Baseline up to Month 15
Reported as:
Median · months
Duration of Response (DR)
monthsSU 37.5 mg, CIS 60 mg/m^2, CAP 1600 mg/m^2SU 37.5 mg, CIS 60 mg/m^2, CAP 2000 mg/m^2SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2
Duration of Response (DR)14.1 (14.1 to 14.1)6.3 (6.0 to 10.9)10.5 (4.4 to 28.1)5.9 (2.8 to 12.8)6.3 (2.5 to 25.5)
SecondaryProgression-Free Survival (PFS)

PFS defined as time from the first dose of study treatment to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first.

Time frame:
Baseline up to Month 15
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsSU 37.5 mg, CIS 60 mg/m^2, CAP 1600 mg/m^2SU 37.5 mg, CIS 60 mg/m^2, CAP 2000 mg/m^2SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2SU 37.5 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2
Progression-Free Survival (PFS)3.2 (2.7 to 9.3)6.6 (2.5 to 8.0)6.4 (4.3 to 13.9)8.0 (4.7 to 9.4)2.8 (2.3 to 11.7)5.5 (4.7 to 10.1)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SU 37.5 mg, CIS 60 mg/m^2, CAP 1600 mg/m^2—1/6 (16.7%)6/6 (100%)
SU 37.5 mg, CIS 60 mg/m^2, CAP 2000 mg/m^2—2/7 (28.6%)7/7 (100%)
SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2—8/15 (53.3%)15/15 (100%)
SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2—8/23 (34.8%)23/23 (100%)
SU 37.5 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2—0/3 (0%)3/3 (100%)
SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2—5/22 (22.7%)22/22 (100%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventSU 37.5 mg, CIS 60 mg/m^2, CAP 1600 mg/m^2SU 37.5 mg, CIS 60 mg/m^2, CAP 2000 mg/m^2SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2SU 37.5 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2
NauseaGastrointestinal disorders1/60/71/150/230/30/22
FatigueGeneral disorders1/60/70/150/230/30/22
CholecystitisHepatobiliary disorders1/60/70/150/230/30/22
Decreased appetiteMetabolism and nutrition disorders1/60/70/150/230/30/22
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/61/71/150/230/32/22
AnaemiaBlood and lymphatic system disorders0/61/70/150/230/30/22
NeutropeniaBlood and lymphatic system disorders0/61/71/150/230/30/22
ThrombocytopeniaBlood and lymphatic system disorders0/61/71/150/230/30/22
Abdominal painGastrointestinal disorders0/61/70/150/230/30/22
Sudden deathGeneral disorders0/61/70/150/230/30/22
Most frequent other events
Showing 10 of 108
Most frequent other events
EventSU 37.5 mg, CIS 60 mg/m^2, CAP 1600 mg/m^2SU 37.5 mg, CIS 60 mg/m^2, CAP 2000 mg/m^2SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2SU 37.5 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2
NeutropeniaBlood and lymphatic system disorders5/66/715/1518/232/318/22
FatigueGeneral disorders6/66/75/159/231/38/22
Decreased appetiteMetabolism and nutrition disorders5/66/711/1515/233/313/22
ThrombocytopeniaBlood and lymphatic system disorders4/66/710/1516/232/38/22
NauseaGastrointestinal disorders3/66/712/1517/232/317/22
StomatitisGastrointestinal disorders5/63/78/1510/231/37/22
AnaemiaBlood and lymphatic system disorders4/64/79/158/231/32/22
Abdominal painGastrointestinal disorders4/64/77/156/231/310/22
ConstipationGastrointestinal disorders4/63/77/158/230/35/22
HyperbilirubinaemiaHepatobiliary disorders0/60/71/155/232/32/22

Baseline characteristics

Age Continuous
Age Continuous(years)SU 37.5 mg, CIS 60 mg/m^2, CAP 1600 mg/m^2SU 37.5 mg, CIS 60 mg/m^2, CAP 2000 mg/m^2SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2SU 37.5 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2Total
Mean55.2 ± 5.850.0 ± 12.450.9 ± 11.354.3 ± 10.163.3 ± 11.650.1 ± 11.552.4 ± 10.9
Sex: Female, Male
Sex: Female, Male(Participants)SU 37.5 mg, CIS 60 mg/m^2, CAP 1600 mg/m^2SU 37.5 mg, CIS 60 mg/m^2, CAP 2000 mg/m^2SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2SU 37.5 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2Total
Female02661823
Male6591721453
08

Study locations

3 sites
  • Pfizer Investigational Site
    Seongnam-si, Gyeonggi-do 463-707, Korea, Republic of
  • Pfizer Investigational Site
    Goyang, Gyeonggi 410-769, Korea, Republic of
  • Pfizer Investigational Site
    Seoul, 110-744, Korea, Republic of
09

References and documents

Publications

  • Lee KW, Park SR, Oh DY, Park YI, Khosravan R, Lin X, Lee SY, Roh EJ, Valota O, Lechuga MJ, Bang YJ. Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer. Invest New Drugs. 2013 Dec;31(6):1547-58. doi: 10.1007/s10637-013-0032-y. Epub 2013 Oct 4. PubMed 24091982 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2008, a primary completion of Aug 2010 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2011, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2007
First posted
Nov 8, 2007
Start
May 2008
Primary completionActual
Aug 2010
CompletionActual
Dec 2011
Results first posted
Sep 5, 2011
Last update
Jan 14, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00555620
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 8, 2007
Start date
May 2008
Primary completion
Aug 2010
Completion
Dec 2011
Results posted
Sep 5, 2011
Last update
Jan 14, 2013

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Oxaliplatin · Cisplatin

Start the discussion